Healius (ASX:HLS) — Material Events
ASX:HLS · 6 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Healius Advances with 3.8% Revenue Growth and Digital Transformation MilestoneMedium
Healius posts 3.8% revenue growth and margin improvement in 1H26, completes digital transformation
18 Feb 2026
·Half Year Results
·85
Healius FY25 Revenue Climbs 5.7% as Lumus Imaging Sale Fuels Cash PositionMedium
Healius FY25 revenue up 5.7%, underlying EBIT meets consensus; Lumus Imaging sale boosts cash; Pathology growth offsets Agilex challenges
21 Aug 2025
·Full Year Results
·80
Healius Secures $60M Pathology Contract with Australian Defence ForceMedium
Healius wins $60M five-year Australian Defence Force pathology services contract
1 Dec 2025
·Major Contract Announcement
·80
Healius Posts 5.7% Revenue Growth Amid Strategic Reset and Cost ChallengesMedium
Healius FY25 revenue up 5.7%, underlying EBIT down 27%, Lumus divestment completed, cost savings underway
21 Aug 2025
·Full Year Results
·75
Healius Eyes Agilex Sale Amid Rising Pathology Costs and Budget FreezeMedium
Healius updates FY 2026 outlook, plans Agilex Biolabs sale amid rising pathology costs and no Federal funding
13 May 2026
·Trading Update
·75
No articles in this tier for the last 12 months.
Market Mentions
2
- appeared in market wrap coverage
These are market wrap articles where Healius (ASX:HLS) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 26 (22 June -> 26 June) 2026
27 June 2026
Healthcare Wrap - Week 8 (16 Feb -> 20 Feb) 2026
21 Feb 2026